Literature DB >> 25332540

A rare entity in multiple myeloma: six nerve paralysis.

Guven Cetin1, M Cem Ar2, Abdullah Cerit3, Kubra Gozubenli3, Simge Erdem3, Gulistan Halac4.   

Abstract

Ophthalmic involvement appears rarely in multiple myeloma (MM). Ophthalmic findings are mostly noted as complications caused by disease or treatment. MM-associated with 6th nerve paralysis is a rare entity. Bortezomib, one of the novel agents used to treat MM, has neurotoxic effect and may cause permanent nerve damage. Herein, we report a 50-year-old male patient with MM who developed the 6th nerve paralysis while receiving bortezomib and discuss its relevant causes.

Entities:  

Keywords:  Bortezomib; Multiple myeloma; The 6th nerve paralysis

Year:  2013        PMID： 25332540      PMCID： PMC4192163          DOI： 10.1007/s12288-013-0252-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  7 in total

1.  Ophthalmic manifestations of multiple myeloma.

Authors:  Shirley Fung; Dinesh Selva; Igal Leibovitch; James Hsuan; John Crompton
Journal:  Ophthalmologica       Date:  2005 Jan-Feb       Impact factor: 3.250

2.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Authors:  T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

3.  Sixth nerve palsy as a presenting sign of intracranial plasmacytoma and multiple myeloma.

Authors:  T Z Movsas; L J Balcer; E R Eggenberger; J L Hess; S L Galetta
Journal:  J Neuroophthalmol       Date:  2000-12       Impact factor: 3.042

4.  Oculomotor nerve palsy associated with bortezomib in a patient with multiple myeloma: a case report.

Authors:  Bassem Toema; Hamdan El-Sweilmeen; Tarek Helmy
Journal:  J Med Case Rep       Date:  2010-10-26

Review 5.  Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

Authors:  Andreas A Argyriou; Gregoris Iconomou; Haralabos P Kalofonos
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

6.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Authors:  Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

7.  Multiple myeloma manifesting as a fluctuating sixth nerve palsy.

Authors:  Jung Hwa Na; Shin Hae Park; Sun Young Shin
Journal:  Korean J Ophthalmol       Date:  2009-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.